EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma

Jun Ren iD, Zohreh Amoozgar iD, Taylor P Uccello, Pin-Ji Lei, Yuhui Zhao, William W Ho iD, Peigen Huang, Alisha Kardian, Stephen C Mack, Dan G Duda iD, Lei Xu, Rakesh K Jain iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2319474122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Jun Ren und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114. Hauptthemen laut MEDLINE: Ependymoma, Receptor, EphB2, Proto-Oncogene Proteins c-abl, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Massachusetts General Hospital (MGH), Cancer Research Institute (CRI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ependymoma (EPN) is a common form of brain tumor in children, often resistant to available cytotoxic therapies. Molecular profiling studies have led to a better understanding of EPN subtypes and revealed a critical role of oncogenes ZFTA–RELA fusion and EPHB2 in supratentorial ependymoma (ST-EPN). However, the immune system’s role in tumor progression and response to therapy remains poorly understood. New treatments for various molecular subtypes of EPN are desperately needed. Using ST-EPN-ZFTA subtype-specific syngeneic mouse models, we found an increased frequency of M2-like tumor-associated macrophages (TAMs), which proportionally increased with tumor size during tumor progression. Transcriptomic profiling of ST-EPN-ZFTA and analysis of a human EPN dataset revealed multiple protein kinases as potential druggable targets. By matching transcriptomic signatures with the target spectrum of FDA-approved drugs, we found that the multikinase inhibitor dasatinib potently inhibited the growth of EPN both in vitro and in vivo, mainly through blocking EPHB2 and ABL1. Treatment with dasatinib reprogrammed the EPN immune microenvironment by polarizing TAMs toward an M1-like phenotype and increasing CD8 T cell activation. Furthermore, dasatinib treatment induced complete regression of established EPN tumors in 78% of the animals and protected survivors against tumor recurrence. Depletion of CD8 cells compromised the durability of EPN responses and reduced overall survival. These data indicate that dasatinib has the potential to be an effective therapy for ST-EPN-ZFTA molecular subgroup of EPN and support further investigation of dasatinib in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpendymomaReceptor, EphB2Proto-Oncogene Proteins c-ablBrain NeoplasmsAnimalsMiceHumansDasatinibDisease Models, AnimalCell Line, TumorProtein Kinase InhibitorsTumor-Associated Macrophages

Stichwörter der Autor:innen

Abl1Ephb2ZFTA-RELAependymomatumor immune microenvironment

Substanzen

Receptor, EphB2DasatinibProto-Oncogene Proteins c-ablEPHB2 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114.
  • Center of Excellence in Neuro-Oncology Sciences, St Jude Children's Research Hospital, Memphis, TN 38105.
  • Neurobiology and Brain Tumor Program, St Jude Children's Research Hospital, Memphis, TN 38105.
  • Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN 38105.
  • Cancer and Cell Biology Program, Baylor College of Medicine, Houston, TX 77030.

ORCID-Profile: Jun Ren, Zohreh Amoozgar, William W Ho, Dan G Duda, Rakesh K Jain

Förderung

  • NCI NIH HHS
  • Massachusetts General Hospital (MGH)
  • Cancer Research Institute (CRI)
  • China Scholarship Council (CSC)
  • Children's Tumor Foundation (CTF)
  • NINDS NIH HHS
  • Aid for Cancer Research (ACR)

Zitieren

APA

Ren, J., Amoozgar, Z., Uccello, T. P., Lei, P. J., Zhao, Y., Ho, W. W., Huang, P., Kardian, A., Mack, S. C., Duda, D. G., Xu, L., & Jain, R. K. (2025). Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2319474122

Vancouver

Ren J, Amoozgar Z, Uccello TP, Lei PJ, Zhao Y, Ho WW, et al. Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2319474122

BibTeX
@article{Ren2025,
  author = {Ren, Jun and Amoozgar, Zohreh and Uccello, Taylor P and Lei, Pin-Ji and Zhao, Yuhui and Ho, William W and Huang, Peigen and Kardian, Alisha and Mack, Stephen C and Duda, Dan G and Xu, Lei and Jain, Rakesh K},
  title = {Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2319474122}
}
Kostenlos starten →